Nerve Growth Factor Gene Therapy in Alzheimer Disease

2007 ◽  
Vol 21 (2) ◽  
pp. 179-189 ◽  
Author(s):  
Mark H. Tuszynski
2005 ◽  
Vol 11 (5) ◽  
pp. 551-555 ◽  
Author(s):  
Mark H Tuszynski ◽  
Leon Thal ◽  
Mary Pay ◽  
David P Salmon ◽  
Hoi Sang U ◽  
...  

Diabetes ◽  
2011 ◽  
Vol 61 (1) ◽  
pp. 229-240 ◽  
Author(s):  
M. Meloni ◽  
B. Descamps ◽  
A. Caporali ◽  
L. Zentilin ◽  
I. Floris ◽  
...  

2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Joo-Yeon Kang ◽  
Dae Young Yoo ◽  
Kwon-Young Lee ◽  
Wooseok Im ◽  
Manho Kim ◽  
...  

2015 ◽  
Vol 72 (10) ◽  
pp. 1139 ◽  
Author(s):  
Mark H. Tuszynski ◽  
Jennifer H. Yang ◽  
David Barba ◽  
Hoi-Sang U ◽  
Roy A. E. Bakay ◽  
...  

2002 ◽  
Vol 19 (1-2) ◽  
pp. 207-207 ◽  
Author(s):  
Mark H. Tuszynski ◽  
Leon Thal ◽  
Hoi-Sang U ◽  
Mary Margaret Pay ◽  
Armin Blesch ◽  
...  

2002 ◽  
Vol 13 (5) ◽  
pp. 1-5 ◽  
Author(s):  
Mark H. Tuszynski ◽  
Hoi Sang U ◽  
John Alksne ◽  
Roy A. Bakay ◽  
Mary Margaret Pay ◽  
...  

The capacity to prevent neuronal degeneration and death during the course of progressive neurological disorders such as Alzheimer disease (AD) would represent a significant advance in therapy. Nervous system growth factors are families of naturally produced proteins that, in animal models, exhibit extensive potency in preventing neuronal death due to a variety of causes, reversing age-related atrophy of neurons, and ameliorating functional deficits. The main challenge in translating growth factor therapy to the clinic has been delivery of growth factors to the brain in sufficient concentrations to influence neuronal function. One means of achieving growth factor delivery to the central nervous system in a highly targeted, effective manner may be gene therapy. In this article the authors summarize the development and implementation of nerve growth factor gene delivery as a potential means of reducing cell loss in AD.


Sign in / Sign up

Export Citation Format

Share Document